T-knife Therapeutics starts Phase I/II trial with its lead candidate against solid tumours

The IMAG1NE trial is designed to evaluate safety and preliminary efficacy of TK-8001. T-knife is using TK-8001 to engineer T cells of patients with solid tumours carrying the melanoma-associated antigen 1 (MAGE-A1) such that they can attack and kill the tumour cells. MAGE-A1 is an attractive therapeutic target that is highly cancer specific and expressed on primary tumours, as well as on metastases. By utilizing biomarker-guided selection criteria, IMAG1NE enrols only those patients having the highest potential for safe, deep, and durable responses.

T-knife was founded by leading T cell and immunology experts based on a technology platform developed at the Max Delbrück Center and supported by Charité – Universitätsmedizin Berlin. Ascenion and the technology transfer team at the Max Delbrück Center have worked closely with the team over many years, securing patent protection for the invention, accompanying its development, and preparing and supporting the foundation of T-knife.

Further information: T-knife’s press release